Craig-Hallum Initiates Coverage On Cardiff Oncology with Buy Rating, Announces Price Target of $8
Portfolio Pulse from Benzinga Newsdesk
Craig-Hallum has initiated coverage on Cardiff Oncology (NASDAQ:CRDF) with a Buy rating and set a price target of $8.

September 06, 2024 | 12:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Craig-Hallum has initiated coverage on Cardiff Oncology with a Buy rating and a price target of $8, indicating a positive outlook for the stock.
The initiation of coverage with a Buy rating and a price target of $8 by Craig-Hallum suggests a positive sentiment towards Cardiff Oncology. This could lead to increased investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100